Steve Engle is CEO of Averigon Consulting, an advisory firm to the life science industry. Previously, Mr Engle was Chairman and CEO of XOMA, a developer of antibody therapeutics for inflammatory, metabolic and other diseases. Prior to that, he was Chairman and CEO of La Jolla Pharmaceutical Company, which discovered the biology of B cell tolerance, developed the first B cell toleragen for lupus patients, and received an approvable letter from the FDA.
Mr Engle served as VP of Marketing for Cygnus, a drug delivery company, where he helped gain FDA approval of and launch Nicotrol for smoking cessation. He was VP of Marketing at a $50 million device company and a management consultant at Strategic Decisions Group and SRI (Stanford Research Institute) International. Mr Engle is a Board member of Anthera Pharmaceuticals with clinical stage products in lupus and enzyme replacement, Prescient Therapeutics (ASX: PTX) with clinical stage oncology products, and AROA Biosurgery, a privately held developer of regenerative medicine products. Mr Engle is a former Board member of BIO, Baybio, BIOCOM and the Lupus Foundation of America. Mr Engle holds a B.S. and an M.S. in electrical engineering with a focus in biomedical engineering from the University of Texas at Austin.
CEO and Managing Director
Steven Yatomi-Clarke has a distinguished career in the Australian capital markets with a particular focus on the life sciences sector, where he has played a leading role as both a corporate advisor and fund raiser to many biotechnology companies. Mr Yatomi-Clarke previously held a position as a Director in Corporate Finance at Patersons Securities.
Educated at the University of Melbourne, where he earned a Bachelor of Science with an Honours Degree in Biochemistry and Molecular Biology, and a Bachelor Commerce majoring in Economics, he has the rare distinction of readily bridging the divide between science and commerce.
He has a strong track record of financing multiple private and public biotechnology companies, bringing more than 15 years’ experience in investment banking with a particular focus on the life sciences/biotechnology sector.
Mr Yatomi-Clarke has consistently been one of the country’s most prolific bankers, involved in primary and secondary offerings, corporate advisory and M&A assignments for medical device and pharmaceutical companies.
Paul Hopper has more than 20 years’ experience in international public company markets, with a focus on start-up and rapid growth companies where he has served as either Chairman, Non-Executive Director or CEO. His focus has been primarily in the life-sciences sector, steering around fourteen public companies in the US, Australia, and Asia.
Paul is an advisor at the Los Angeles-based Cappello Group where he is Head of the Life Sciences and Biotechnology Group responsible for mergers and acquisitions and capital raisings focusing on the biotechnology and life sciences sectors.
He is an Executive Chairman of Imugene ltd, Chairman of Viralytics Ltd and founder of Pathway Oncology.
Dr James Campbell brings to Prescient a solid track record as a scientist and commercial executive. He was previously the Chief Financial Officer and Chief Operating Officer of Chemgenex, which was acquired by Cephalon for $230 million in 2011.
His responsibilities ranged from IP management to licensing and business development and as a member of the executive team, he helped steer and transform the company from a $10 million research based entity to a company with completed clinical trials and regulatory dossiers submitted to the FDA and EMA before its $230 million sale.
More recently he guided the creation of Invion Limited (ASX: IVX) as a non-executive director and retains this role.
Dr Campbell also has experience advising private biotechnology companies in the US and New Zealand with capital raisings and partnering negotiations.